Low Dose Naltrexone for Glioma Patients

NCT01303835 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Malignant Glioma

Interventions

DRUG: LDN
DRUG: Placebo

Sponsor

Katy Peters